Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment simplification strategies news

Show

From To
New and experimental HIV treatments
HIV Drugs in the Pipeline: Expected Approvals for 2018

Three specialty HIV medications—three oral medications and one IV formulation—are expected to receive FDA approval in 2018. All of them are combination products geared toward improving adherence.

Published
31 December 2017
From
Infectious Disease Special Edition
Treatment simplification strategies
Could we safely reduce the frequency of treatments for HIV-positive people?

Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

Published
08 December 2017
From
The Conversation
HIV treatment
Top 10 HIV Clinical Developments of 2017

By David Alain Wohl, M.D., professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC).

Published
19 November 2017
From
The Body Pro
New and experimental HIV treatments
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group
New and experimental HIV treatments
ViiV Healthcare Files Regulatory Submissions for First Two-Drug HIV Maintenance Regimen

GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced regulatory submissions to the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for a single-tablet, two-drug regimen of dolutegravir (Tivicay, ViiV Healthcare) and rilpivirine (Edurant, Janssen Sciences Ireland UC) for the maintenance treatment of HIV-1 infection.

Published
02 June 2017
From
ViiV
Changing treatment
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

Published
20 December 2016
From
Wall Street Journal
New and experimental HIV treatments
Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen

Janssen Sciences Ireland UC (Janssen) today announced that two Phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug (integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen to the two drug regimen of rilpivirine (Janssen) and dolutegravir (ViiV Healthcare) met the primary endpoint of non inferiority at week 48.

Published
20 December 2016
From
Janssen press release
Pharmaceutical industry
Glaxo Bets It Can Shake Up HIV Treatment

GlaxoSmithKline PLC is pinning the future of its HIV business on an audacious bet. They hope their latest HIV pill is powerful enough to suppress the virus with the help of just one other drug.

Published
30 August 2016
From
Wall Street Journal
New and experimental HIV treatments
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Published
16 August 2016
From
ViiV press release
New and experimental HIV treatments
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
← Prev1234Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.